SuperworthCelularity EV/EBIT CELU
Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2020.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 1.7×
- Nov 2024
- 6-year median
- 2.3×
- 6-year range
- 1.1× to 22.4×
- Peer median
- 3.7×
Celularity's EV/EBIT is not a meaningful number today: no quarters with one-off gains and charges taken out yet.
It was last meaningful in Nov 2024, at 1.7×.
On the days it had one over the last 6 years, its median was 2.3×, from 1.1× in Aug 2021 to 22.4× in Mar 2022.
EV/EBIT over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2024 | 1.7× | 1.3× | 4.0× |
| 2023 | 1.7× | 1.4× | 2.2× |
| 2022 | 18.0× | 9.5× | 22.4× |
| 2021 | 12.1× | 1.1× | 17.0× |
| 2020 | 3.2× | 3.0× | 3.5× |
Against its peers
Companies in Drug Manufacturers - General nearest Celularity's size, closest first, today.
| Company | EV/EBIT |
|---|---|
| CELUCelularity | n/m |
| ATNMActinium Pharmaceuticals | 1.2× |
| SPROSpero Therapeutics | 2.1× |
| LFVNLifevantage | 9.6× |
| NATRNatures Sunshine Products | 5.2× |
| Peer median | 3.7× |
What the EV/EBIT tells you
What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.
Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.
More on Celularity
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.